OpPacli (optimized paclitaxel) / Pharma in silica - LARVOL DELTA

4 M$ investment agreement to prepare the clinical study of an improved chemotherapy (Canada Newswire) - "Pharma in silica inc. announces today a $4,000,000 investment agreement in order to bring OpPacli, its lead drug candidate, to the threshold of a North American clinical study. A first tranche of $1,500,000 was disbursed, in equal parts by nine accredited investors and by Investissement Québec as the agent of Gouvernement du Québec via the Impulsion PME program (pharmaceutical section). The second tranche, which could reach $2.5 million, will be concluded momentarily....The OpPacli nano-sized silica sphere is designed to reduce the toxicity and increase the efficacy of paclitaxel, a cytotoxic drug sold each year at the pace of US$3 billion."

Commercial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Paclitaxel-loaded elastic liposomes synthesised by microfluidics technique for enhance transdermal delivery. (PubMed, Drug Deliv Transl Res) - "Furthermore, physiochemical characterisation was performed on the optimised Paclitaxel-loaded EL using a variety of methods, including Dynamic Light Scattering, Fourier Transform Infrared Spectroscopy, Atomic force microscopy, elasticity, encapsulation efficiency, and In vitro release. The Tween 80 formulations with optimised concentration provide the most suitable size and higher encapsulation efficiency. The release profile of the formulations showed more immediate release from the EL with higher edge activator concentration and a higher % of the released dug from the Tween 80 formulations."

Journal • Skin Cancer